Regenerative Medicine for Cartilage Market Report 2026

The regenerative medicine for cartilage market size has grown strongly in recent years. It will grow from $4.68 billion in 2025 to $4.96 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising incidence of knee osteoarthritis, increasing sports-related cartilage injuries, limitations of conventional pain management therapies, growing orthopedic surgical volumes, early adoption of autologous chondrocyte implantation.

The regenerative medicine for cartilage market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancements in regenerative biologics, increasing geriatric population, rising demand for joint preservation therapies, expansion of outpatient surgical centers, improving reimbursement for regenerative treatments. Major trends in the forecast period include expansion of autologous chondrocyte implantation procedures, rising adoption of minimally invasive cartilage repair surgeries, increasing clinical validation of stem cell-based cartilage therapies, growing demand for long-lasting knee cartilage regeneration solutions, standardization of cartilage repair protocols in orthopedic practice.

The increasing prevalence of chronic diseases is expected to drive the growth of the regenerative medicine for cartilage market. Chronic diseases are long-lasting medical conditions that often require ongoing management and care. The rising incidence of chronic diseases, particularly those affecting the musculoskeletal system, has highlighted the need for advanced therapeutic solutions such as regenerative medicine for cartilage. For instance, in June 2024, according to the National Health Service, a UK-based government agency, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the growing burden of chronic conditions is fueling demand for regenerative cartilage therapies.

Key companies in the regenerative medicine for cartilage market are focusing on the development of bioactive materials to enhance cartilage regeneration and improve patient outcomes. Bioactive materials are engineered to mimic the natural extracellular matrix, promoting cell proliferation, differentiation, and tissue repair. For example, in August 2024, researchers at Northwestern University, a US-based private research university, developed a bioactive material that successfully regenerated high-quality hyaline cartilage in a sheep model. The material combines a bioactive peptide that binds to transforming growth factor beta-1 (TGF-β1) with chemically modified hyaluronic acid, facilitating self-organization of nanoscale fibers that emulate natural cartilage formation and enhance tissue repair. This innovation has the potential to prevent knee replacements and treat degenerative joint diseases.

In November 2023, Smith & Nephew, a UK-based medical technology company, acquired CartiHeal, an Israel-based company specializing in cartilage and osteochondral defect treatments, for an undisclosed amount. The acquisition strengthens Smith & Nephew’s orthopedic portfolio, enhancing its capabilities in cartilage repair and regeneration, and enabling the company to better address the rising demand for advanced orthopedic solutions globally.

Major companies operating in the regenerative medicine for cartilage market are Smith & Nephew plc, Integra LifeSciences, Stryker Corporation, MiMedx Group Inc., Zimmer Biomet Holdings Inc., B. Braun Melsungen AG, AbbVie, CONMED Corporation, Arthrex Inc., Baxter International Inc., China Regenerative Medicine International, ABLbio, Cellgenix GmbH, BioTissue Technologies, Corin Group, Medical Import Ltd., Orthonika, Merete, 3di GmbH, Aditus Medical GmbH, Anton Hipp GmbH, AREX SAS, Acelity L.P. Inc., StemCells Inc, Organogenesis Inc, NuVasive Inc, Japan Tissue Engineering Co. Ltd, Advantagene Inc., Mesoblast Ltd, Globus Medical, DePuy Synthes, Cryolife Inc, Johnson & Johnson, Medtronic Plc, Rti Surgical, CartiHeal Inc., DJO Global Inc., Wright Medical Group, Auxein, Aesculap Inc, AMEGA Biotech.

Europe was the largest region in regenerative medicine for cartilage in 2025. The regions covered in the regenerative medicine for cartilage market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regenerative medicine for cartilage market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the regenerative medicine for cartilage market by increasing costs of imported cell culture media, bioreactors, scaffolds, and specialized surgical consumables used in cartilage repair procedures. These cost pressures have particularly affected cell-based and tissue-based segments, with hospitals and clinics in North America and Asia-Pacific experiencing higher procurement expenses due to reliance on global biotech supply chains. Regions dependent on cross-border sourcing of laboratory-grade materials face delayed procedures and pricing challenges. However, tariffs are also encouraging localized manufacturing, regional partnerships, and domestic production of regenerative components, which may strengthen long-term supply resilience and innovation capacity.

The regenerative medicine for cartilage market research report is one of a series of new reports that provides regenerative medicine for cartilage market statistics, including regenerative medicine for cartilage industry global market size, regional shares, competitors with a regenerative medicine for cartilage market share, detailed regenerative medicine for cartilage market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative medicine for cartilage industry. This regenerative medicine for cartilage market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Regenerative medicine for cartilage involves treatments used during surgery to repair damaged knee cartilage using the patient’s own cells capable of generating new cartilage. Chondrocytes, the cells responsible for producing cartilage, are collected via biopsy, expanded in a laboratory, and then implanted into the damaged area during surgery.

The main types of regenerative medicine for cartilage include cell-based, gene-based, and tissue-based approaches. Cell-based therapies involve processes, technologies, or products derived from living cells. These treatments are applied in areas such as musculoskeletal disorders, oncology, dental care, wound care, and others, and are utilized by end-users including ambulatory surgical centers, hospitals, clinics, and similar healthcare facilities.

The regenerative medicine for cartilage market consists of sales of cartilage regeneration, platelet-rich plasma (PRP), and prolotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.